• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS、MERS 和 COVID-19 感染的免疫反应比较,疫苗设计和开发的视角。

Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.

机构信息

Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

出版信息

Biomed Res Int. 2021 Jan 22;2021:8870425. doi: 10.1155/2021/8870425. eCollection 2021.

DOI:10.1155/2021/8870425
PMID:33564683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7841448/
Abstract

Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus Disease 2019 (COVID-19) infections are the three epidemiological diseases caused by the Coronaviridae family. Perceiving the immune responses in these infections and the escape of viruses could help us design drugs and vaccines for confronting these infections. This review investigates the innate and adaptive immune responses reported in the infections of the three coronaviruses SARS, MERS, and COVID-19. Moreover, the present study can trigger researchers to design and develop new vaccines and drugs based on immune system responses. In conclusion, due to the need for an effective and efficient immune stimulation against coronavirus, a combination of several strategies seems necessary for developing the vaccine.

摘要

严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和 2019 年冠状病毒病(COVID-19)感染是由冠状病毒科引起的三种流行病学疾病。了解这些感染中的免疫反应和病毒的逃逸机制可以帮助我们设计药物和疫苗来对抗这些感染。本综述研究了 SARS、MERS 和 COVID-19 三种冠状病毒感染中报道的先天和适应性免疫反应。此外,本研究可以促使研究人员根据免疫系统反应设计和开发新的疫苗和药物。总之,由于需要针对冠状病毒进行有效和高效的免疫刺激,因此似乎需要结合几种策略来开发疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/231b8033ef34/BMRI2021-8870425.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/dd732c089609/BMRI2021-8870425.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/e8689894aef2/BMRI2021-8870425.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/231b8033ef34/BMRI2021-8870425.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/dd732c089609/BMRI2021-8870425.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/e8689894aef2/BMRI2021-8870425.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b2f/7841448/231b8033ef34/BMRI2021-8870425.003.jpg

相似文献

1
Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.SARS、MERS 和 COVID-19 感染的免疫反应比较,疫苗设计和开发的视角。
Biomed Res Int. 2021 Jan 22;2021:8870425. doi: 10.1155/2021/8870425. eCollection 2021.
2
Lessons for COVID-19 Immunity from Other Coronavirus Infections.其他冠状病毒感染带来的 COVID-19 免疫经验教训。
Immunity. 2020 Aug 18;53(2):248-263. doi: 10.1016/j.immuni.2020.07.005. Epub 2020 Jul 14.
3
SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.严重急性呼吸综合征冠状病毒2:既往冠状病毒、免疫反应及疫苗研发
Bol Med Hosp Infant Mex. 2020;77(5):252-261. doi: 10.24875/BMHIM.20000191.
4
Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.基于 SARS 和 MERS 疫苗研发进展的 COVID-19 疫苗研发的挑战与前景。
Transbound Emerg Dis. 2021 May;68(3):1111-1124. doi: 10.1111/tbed.13804. Epub 2020 Sep 23.
5
Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.先天免疫对高致病性冠状病毒和其他重要呼吸道病毒感染的反应。
Front Immunol. 2020 Aug 18;11:1979. doi: 10.3389/fimmu.2020.01979. eCollection 2020.
6
Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.对 SARS-CoV、MERS-CoV 和 SARS-CoV-2 的免疫反应。
Adv Exp Med Biol. 2020;1288:5-12. doi: 10.1007/5584_2020_549.
7
Coronavirus vaccine development: from SARS and MERS to COVID-19.冠状病毒疫苗的研发:从 SARS 和 MERS 到 COVID-19。
J Biomed Sci. 2020 Dec 20;27(1):104. doi: 10.1186/s12929-020-00695-2.
8
Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.SARS-CoV、MERS-CoV 和 SARS-CoV-2 感染中的免疫致病反应和血液病理效应的重点。
Front Immunol. 2020 May 12;11:1022. doi: 10.3389/fimmu.2020.01022. eCollection 2020.
9
Research progress and challenges to coronavirus vaccine development.冠状病毒疫苗研发的研究进展和挑战。
J Med Virol. 2021 Feb;93(2):741-754. doi: 10.1002/jmv.26517. Epub 2020 Oct 7.
10
[Strategies for vaccine development of COVID-19].[新型冠状病毒肺炎疫苗研发策略]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):593-604. doi: 10.13345/j.cjb.200094.

引用本文的文献

1
Potential blocker of SARS-CoV entry and a narrow functionality of its spike protein motifs on Qubevirus platform.严重急性呼吸综合征冠状病毒(SARS-CoV)进入的潜在阻断剂及其刺突蛋白基序在库贝病毒平台上的狭窄功能。
J Biol Chem. 2025 Jun 12;301(7):110371. doi: 10.1016/j.jbc.2025.110371.
2
Global research trends of immunosenescence and immunotherapy: A bibliometric study.免疫衰老与免疫治疗的全球研究趋势:一项文献计量学研究。
Hum Vaccin Immunother. 2025 Dec;21(1):2469403. doi: 10.1080/21645515.2025.2469403. Epub 2025 Feb 24.
3
Social support, health literacy and anxiety among pregnant women during coronavirus 2019 pandemic in Thailand.

本文引用的文献

1
DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.基于树突状细胞的疗法:严重 SARS-CoV-2 感染的潜在策略。
Int J Med Sci. 2021 Jan 1;18(2):406-418. doi: 10.7150/ijms.47706. eCollection 2021.
2
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.严重急性呼吸综合征冠状病毒2刺突糖蛋白的结构、功能及抗原性
Cell. 2020 Dec 10;183(6):1735. doi: 10.1016/j.cell.2020.11.032.
3
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
2019年冠状病毒病大流行期间泰国孕妇的社会支持、健康素养与焦虑状况
Front Psychol. 2023 Dec 21;14:1246996. doi: 10.3389/fpsyg.2023.1246996. eCollection 2023.
4
Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.乌干达不同疾病表型的 SARS-COV-2 患者的免疫和生化生物标志物改变。
BMC Infect Dis. 2023 Dec 6;23(1):857. doi: 10.1186/s12879-023-08854-0.
5
Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.评估 MERS-CoV 感染和 SARS-CoV-2 疫苗接种患者中的广谱反应。
JAMA Netw Open. 2023 Jun 1;6(6):e2319222. doi: 10.1001/jamanetworkopen.2023.19222.
6
Vaccine development for mosquito-borne viral diseases.蚊媒病毒病疫苗的研发。
Front Immunol. 2023 May 12;14:1161149. doi: 10.3389/fimmu.2023.1161149. eCollection 2023.
7
Evaluation of Tcell exhaustion based on the expression of EOMES, Tbet and co-inhibitory receptors in severe and non-severe covid-19 patients.基于EOMES、Tbet表达及共抑制受体对重症和非重症新冠患者T细胞耗竭的评估
Gene Rep. 2023 Jun;31:101747. doi: 10.1016/j.genrep.2023.101747. Epub 2023 Feb 2.
8
Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster.在接受疫苗加强针之前接受过利妥昔单抗治疗的血液肿瘤疾病患者中,对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)有强烈的体液免疫反应,但细胞免疫反应不强。
Cancers (Basel). 2022 Nov 10;14(22):5537. doi: 10.3390/cancers14225537.
9
Association between expression of ZBP1, AIM2, and MDA5 genes and severity of COVID-19.ZBP1、AIM2和MDA5基因表达与新型冠状病毒肺炎严重程度的关联
EXCLI J. 2022 Sep 1;21:1171-1183. doi: 10.17179/excli2022-5141. eCollection 2022.
10
A review of the effect of COVID-19 on immune responses of the body.新型冠状病毒肺炎对机体免疫反应影响的综述。
J Family Med Prim Care. 2022 May;11(5):1624-1632. doi: 10.4103/jfmpc.jfmpc_677_21. Epub 2022 May 14.
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
4
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.SARS-CoV-2 中和抗体结构为治疗策略提供信息。
Nature. 2020 Dec;588(7839):682-687. doi: 10.1038/s41586-020-2852-1. Epub 2020 Oct 12.
5
Investigation of immune cells on elimination of pulmonary-Infected COVID-19 and important role of innate immunity, phagocytes.研究免疫细胞在清除肺部感染的 COVID-19 中的作用以及固有免疫、吞噬细胞的重要作用。
Rev Med Virol. 2021 Mar;31(2):e2158. doi: 10.1002/rmv.2158. Epub 2020 Sep 18.
6
Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.新型冠状病毒肺炎的细胞和分子途径及潜在治疗干预点
Front Pharmacol. 2020 Jul 29;11:1169. doi: 10.3389/fphar.2020.01169. eCollection 2020.
7
The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.SARS-CoV-2 刺突突变对病毒感染力和抗原性的影响。
Cell. 2020 Sep 3;182(5):1284-1294.e9. doi: 10.1016/j.cell.2020.07.012. Epub 2020 Jul 17.
8
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.追踪 SARS-CoV-2 刺突蛋白的变化:D614G 增加 COVID-19 病毒感染力的证据。
Cell. 2020 Aug 20;182(4):812-827.e19. doi: 10.1016/j.cell.2020.06.043. Epub 2020 Jul 3.
9
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.通用设计的贝塔冠状病毒疫苗,用于预防 COVID-19、MERS 和 SARS。
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
10
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.来自 COVID-19 患者的强效中和抗体定义了多个易损目标。
Science. 2020 Aug 7;369(6504):643-650. doi: 10.1126/science.abc5902. Epub 2020 Jun 15.